Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Japan to rejuvenate pharma landscape with new Government fund and policy reforms, says GlobalData

Japan’s Ministry of Health, Labor, and Welfare (MHLW) announced a new 10 year government fund in January 2025 to support innovative drug development. The initiative signals a stronger push towards pro-innovation policies, aiming to strengthen drug discovery capabilities and build a more resilient pharmaceutical ecosystem in the country, says GlobalData, a leading data and analytics […]
Read more

South Korea and China stand at forefront of degrader antibody-conjugate development in oncology and other indications, says GlobalData

The emergence of degrader-antibody conjugates (DACs) has attracted much attention, with a potential to transform the precision medicine landscape. DACs aim to address the limitations of traditional antibody-drug conjugates (ADCs) that combine the specificity of antibodies with the potency of protein degraders. DACs represent an emerging class of targeted therapy, with South Korea and China […]
Read more

FDA drug approvals drop 15.44%, but smaller pharma leads innovation, reveals GlobalData bio/pharmaceutical outsourcing report

Innovator and biosimilar drug approvals by the FDA have declined by 15.44%, from 149 in 2023 to 126 in 2024. Despite this downturn, the landscape of pharmaceutical innovation remains vibrant, particularly among smaller companies, which are making significant strides in addressing unmet medical needs, says GlobalData, a leading data and analytics company. GlobalData’s Bio/Pharmaceutical Outsourcing […]
Read more

Blood cancers dominate CAR-T pipeline, reveals GlobalData

Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene therapies (CGT). The CAR-T landscape is dominated by blood cancers, with industry leaders like Bristol Myers Squibb at the forefront of this revolution, driving advancements that have the potential to redefine treatment paradigms for blood cancers, such as […]
Read more

NHS approval of endometriosis therapy Ryeqo enhances patient care, eases healthcare strain, says GlobalData

The National Health Service (NHS) in England has approved Gedeon Richter’s Ryeqo, the first long-term pill available for endometriosis for patients who have exhausted all other treatment options. The approval addresses the long-standing gap in long-term treatment options for endometriosis, improving overall disease management while easing the burden on healthcare resources, says GlobalData, a leading […]
Read more

IA-2A positivity could help develop effective intervention strategies in type 1 diabetes progression, says GlobalData

A recent study published in Springer Medizin has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a significant biomarker for disease progression in individuals at risk of type 1 diabetes (T1D). The findings are particularly relevant as the T1D market undergoes a transformation driven by advancements in predictive diagnostics and disease-modifying therapies. This discovery enhances […]
Read more

Lerodalcibep could become key option for patients requiring additional LDL-C reduction beyond existing therapies, says GlobalData

LIB Therapeutics (LIB) recently announced that the FDA has accepted its Biologics License Application (BLA) for lerodalcibep, a novel therapy designed to lower low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) or those at high or very high risk of developing ASCVD. If approved, lerodalcibep could be a key treatment option for […]
Read more

Sionna Therapeutics’ NBD1 stabilizers hold potential to differentiate from Vertex’s existing therapies in cystic fibrosis, says GlobalData

Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic fibrosis (CF). With Vertex Pharmaceuticals maintaining a dominant position in the CF treatment landscape through its CFTR modulator franchise, Sionna is looking to introduce its NBD1 stabilizers, SION-719 and SION-451, […]
Read more

Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData

The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion in 2033, driven by the recent approvals of innovative therapies such as Sarepta Therapeutics and Roche’s Elevidys (delandistrogene moxeparvovec), and Santhera Pharmaceuticals’ Agamree (vamorolone), according to GlobalData, a leading data and […]
Read more

Areteia’s dexpramipexole holds potential to redefine respiratory health, says GlobalData

During the J.P. Morgan 43rd Annual Healthcare Conference in January 2025, Areteia Therapeutics’s CEO, Jorge Bartolome, presented a detailed review of its achievements in 2024 and outlined its 2025 plans to advance innovation in the respiratory space with its flagship candidate dexpramipexole dihydrochloride, the first oral therapy targeting eosinophilic asthma. With multiple ongoing clinical trials […]
Read more
1 … 11 12 13 14 15 … 110